Global Eating Disorder Market, By Type (Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder, Pica, Rumination Disorder, Avoidant/Restrictive Food Intake Disorder, Purging Disorder, Night Eating Syndrome, Others), Treatment (Medications, Therapies, Others), Patients (Inpatients, Outpatients), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Eating Disorder Market
The eating disorder market is expected to witness market growth at a rate of 5.8% in the forecast period of 2022 to 2029. Data Bridge Market Research report on eating disorder market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in healthcare sector globally is escalating the growth of eating disorder market.
Eating disorder refers to a complex mental health condition that usually requires psychiatric and medical assistance. A common misconception exists regarding eating habits such as overeating eating is healthy lifestyle choice. The disorder might develop with obsession with food, body weight and size that leads to some serious health problems including diabetes, cardiovascular diseases, anxiety, and depression, among others.
The rise in the prevalence of binge eating disorder across the globe acts as one of the major factors driving the growth of eating disorder market. The increase in the incidences of obesity among population and rise in occurrence of eating disorder especially among women accelerate the market growth. The rise in Research and Development in pharmaceutical companies for enhancing the treatment and surge in government initiatives to increase the awareness further influence the market. Additionally, surge in healthcare expenditure, development in technology, supportive government legislation and rise in social media influence positively affect the eating disorder market. Furthermore, research on new indications extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, concerns regarding side-effects of the treatment and stigma associated with the eating disorder are expected to obstruct the market growth. The lack of awareness regarding the disorder is projected to challenge the eating disorder market in the forecast period of 2022-2029.
This eating disorder market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info eating disorder market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Eating Disorder Market Scope and Market Size
The eating disorder market is segmented on the basis of type, treatment, patients, route of administration, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the eating disorder market is segmented into anorexia nervosa, bulimia nervosa, binge eating disorder, pica, rumination disorder, avoidant/restrictive food intake disorder, purging disorder, night eating syndrome and others.
- On the basis of treatment, the eating disorder market is segmented into medications, therapies and others. Treatment by medication is further segmented into antidepressants, antipsychotics, mood stabilizers and others. Therapies is further segmented into cognitive behavioural therapy, family-based therapy and other.
- On the basis of patients, the eating disorder market is segmented into inpatients and outpatients.
- On the basis of route of administration, the eating disorder market is segmented into oral, parenteral, topical and others.
- On the basis of end-users, the eating disorder market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the eating disorder market has also been segmented into hospital pharmacy, retail pharmacy and others.
Eating Disorder Market Country Level Analysis
The eating disorder market is analyzed and market size information is provided by country, type, treatment, patients, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global eating disorder market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the eating disorder market due to the high prevalence of obesity among population within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the large population in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The eating disorder market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Eating Disorder Market Share Analysis
The eating disorder market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related eating disorder market.
Some of the major players operating in the eating disorder market are Bausch & Lomb Incorporated, Apotex Inc., Somerset Therapeutics, LLC, Mylan N.V., Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceutical LLC., Eli Lilly and Company. AbbVie Inc., and GlaxoSmithKline Plc among others.